News

Find updates on the work of our researchers here, as well as news about recent advances in Alzheimer's science, funding and awareness.

Sherry Sharp, Wife of CarMax Founder, Joins Board of Directors

Sherry Sharp, wife of CarMax founder Richard L. Sharp, today announced that she has agreed to serve on Cure Alzheimer’s Fund’s Board of Directors. In her husband’s honor, she is going to do everything she can to further our mission to fund research with the highest probability of preventing, slowing, or reversing Alzheimer’s disease through venture-based philanthropy.

A Trio of Breakthroughs

Recent months have witnessed three remarkable developments in projects supported by Cure Alzheimer’s Fund.

Featured Researcher: Charles G. Glabe, Ph.D.

From the age of 2, when he disassembled his brother’s mechanical duck and his father praised him for his curiosity, Charlie Glabe was always interested in the way things work. Today, Charlie is a highly respected neuroscientist and a member of the Cure Alzheimer’s Fund Research Consortium.

“Game Changer”: New York Times trumpets “giant step forward” by Tanzi lab

For the first time, and to the astonishment of many of their colleagues, researchers created what they call Alzheimer’s in a Dish — a petri dish with human brain cells that develop the telltale structures of Alzheimer’s disease.

Remembering Stephen F. Heinemann

Cure Alzheimer's Fund is saddened by the recent passing of Stephen F. Heinemann, a pioneer in brain disease research and a former member of our Scientific Advisory Board. Dr. Heinemann, who was based at the Salk Institute for Biological Studies, passed away earlier this month at age 75.

An “Inside-Out View” of Alzheimer’s: Study Offers New Take on Amyloid Hypothesis

A new "alternative amyloid hypothesis” from the lab of Dr. Charles Glabe, at the University of California at Irvine, helps explain precisely how neurons (nerve cells) die in Alzheimer’s disease and how known genetic mutations initiate a chain reaction in this long process. The important new hypothesis was driven by research supported by Cure Alzheimer’s Fund, and has just been being published in the Journal Neurobiology of Disease. Dr.

Are Brain Cell Regeneration Drugs Ready for Prime Time?

A promising first-in-class drug stimulates the creation of new nerve cells in the brains of Alzheimer's mice and will soon be tested in the brains of human patients, thanks to new research by Dr. Sam Gandy, member of Cure Alzheimer's Fund's Research Consortium, at Mount Sinai School of Medicine in New York.

16 Cure Alzheimer’s Fund Scientists Listed Among World’s Most Influential

A prestigious new list of the "World's Most Influential Scientific Minds" includes 16 scientists closely associated with Cure Alzheimer's Fund.

Interview with William Mobley, M.D., Ph.D.

Born in landlocked Nebraska, William Mobley discovered the wonders of research when he first studied a sea cucumber’s hemoglobin. Now a prominent academic neurologist and the newest member of Cure Alzheimer’s Fund’s Scientific Advisory Board, Mobley’s passion for science and for living life never has waned.

Alzheimer’s and Down Syndrome: Overlap and Opportunity

The world already is very familiar with both Alzheimer’s disease (AD), primarily a disease that occurs in the elderly, and Down syndrome (DS), a genetic condition present at birth. What many don’t realize is that these two conditions also overlap. By age 40, nearly all people born with Down syndrome have begun accruing the plaque and tangle hallmarks of Alzheimer’s. By age 60, most exhibit signs of dementia.